[
  {
    "ts": "2025-12-23T01:09:58+00:00",
    "headline": "Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug",
    "summary": "The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-jumps-fda-oks-wegovy-pill-first-oral-glp-1-weight-loss-drug/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8daff7dd-6122-3cb9-ad16-8a3df5fa8764",
      "content": {
        "id": "8daff7dd-6122-3cb9-ad16-8a3df5fa8764",
        "contentType": "STORY",
        "title": "Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug",
        "description": "",
        "summary": "The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.",
        "pubDate": "2025-12-23T01:09:58Z",
        "displayTime": "2025-12-23T01:09:58Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8daff7dd-6122-3cb9-ad16-8a3df5fa8764/novo-nordisk-jumps-as-fda-oks.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YiKgI2utbRoeUo10UfMm9A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wGfYYRb5xDf1JRG.uzPz.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9df63cff834c89a486567ccbf9cf93d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-stock-jumps-fda-oks-wegovy-pill-first-oral-glp-1-weight-loss-drug/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T00:29:18+00:00",
    "headline": "Why Abivax Stock Was on Fire Today",
    "summary": "Investors were excited about the possibility of a buyout with a high price tag.",
    "url": "https://www.fool.com/investing/2025/12/22/why-abivax-stock-was-on-fire-today/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "332eba4d-b714-3d48-8a2a-a0a1ee18efe1",
      "content": {
        "id": "332eba4d-b714-3d48-8a2a-a0a1ee18efe1",
        "contentType": "STORY",
        "title": "Why Abivax Stock Was on Fire Today",
        "description": "",
        "summary": "Investors were excited about the possibility of a buyout with a high price tag.",
        "pubDate": "2025-12-23T00:29:18Z",
        "displayTime": "2025-12-23T00:29:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45",
          "originalWidth": 1400,
          "originalHeight": 935,
          "caption": "Person in white lab coat inspecting pharmacy shelves.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RpHO07p4Wy7kIzvpj1E8tA--~B/aD05MzU7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45.cf.webp",
              "width": 1400,
              "height": 935,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4orWm0qM6SFVqYvBE_TnGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bf90746a10c9f788c7f13ae8f4931b45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/22/why-abivax-stock-was-on-fire-today/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-abivax-stock-fire-today-002918711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T05:16:14+00:00",
    "headline": "Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "690e6da6-9d98-3549-9fc1-298cfd6447f3",
      "content": {
        "id": "690e6da6-9d98-3549-9fc1-298cfd6447f3",
        "contentType": "STORY",
        "title": "Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […]",
        "pubDate": "2025-12-23T05:16:14Z",
        "displayTime": "2025-12-23T05:16:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "SLG"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "TSM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:24:00+00:00",
    "headline": "GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly",
    "summary": "The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t",
    "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "cca6e038-8238-32de-b5f8-b7c98131cac4",
      "content": {
        "id": "cca6e038-8238-32de-b5f8-b7c98131cac4",
        "contentType": "STORY",
        "title": "GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market is Expected to Grow Significantly",
        "description": "",
        "summary": "The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at a CAGR of 13.0%. Driven by expanding indications, the market sees robust demand amid rising chronic conditions like obesity and diabetes. Patented products dominated the market in 2024, while biosimilars are projected to rise post-2026, following patent expiry. In 2024, home-care settings led the market by end user due to rising self-administration trends. The US helmed t",
        "pubDate": "2025-12-23T09:24:00Z",
        "displayTime": "2025-12-23T09:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "GLP-1 Agonists Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T_Uf2N6aoGqSZF7HD6kbng--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xXR2G_pm2FrjJy91u1wQGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82d40e331f64560470008fc17d786c66.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/glp-1-agonists-ozempic-wegovy-092400244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:10:24+00:00",
    "headline": "Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill",
    "summary": "Investing.com -- Shares in Novo Nordisk jumped Tuesday after the company won U.S. approval for its GLP-1 weight-loss pill, marking the first time such a treatment has been cleared in oral form.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "a9b49c38-57ca-3601-8229-a731d321b787",
      "content": {
        "id": "a9b49c38-57ca-3601-8229-a731d321b787",
        "contentType": "STORY",
        "title": "Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill",
        "description": "",
        "summary": "Investing.com -- Shares in Novo Nordisk jumped Tuesday after the company won U.S. approval for its GLP-1 weight-loss pill, marking the first time such a treatment has been cleared in oral form.",
        "pubDate": "2025-12-23T09:10:24Z",
        "displayTime": "2025-12-23T09:10:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-jump-fda-091024692.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:00:04+00:00",
    "headline": "Trending tickers: Tesla, Novo Nordisk, Starfighters Space, and Pets at Home",
    "summary": "The latest investor updates on stocks that are trending on Tuesday",
    "url": "https://uk.finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "28b542c5-f7a6-4533-b9dd-885ea875cdee",
      "content": {
        "id": "28b542c5-f7a6-4533-b9dd-885ea875cdee",
        "contentType": "STORY",
        "title": "Trending tickers: Tesla, Novo Nordisk, Starfighters Space, and Pets at Home",
        "description": "",
        "summary": "The latest investor updates on stocks that are trending on Tuesday",
        "pubDate": "2025-12-23T09:00:04Z",
        "displayTime": "2025-12-23T09:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a",
          "originalWidth": 5720,
          "originalHeight": 3908,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4cS7rakNv0m_GxYKfwR6vg--~B/aD0zOTA4O3c9NTcyMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a.cf.webp",
              "width": 5720,
              "height": 3908,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZKYm7xZkCB6MWDW0xayMgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/01fa1930-df2f-11f0-bfaf-506e74a47a6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tesla-novo-nordisk-starfighters-space-pets-at-home-trending-tickers-090004894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "BYDDF"
            },
            {
              "symbol": "BYDDY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "PAHGF"
            },
            {
              "symbol": "PHGPY"
            },
            {
              "symbol": "JSAIY"
            },
            {
              "symbol": "JSNSF"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "002594.SZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SBRY.L"
            },
            {
              "symbol": "LMT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T10:05:00+00:00",
    "headline": "Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy",
    "summary": "Novo Nordisk  shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill.  The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and  Eli Lilly’s  Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution.  Shares in Novo Nordisk rose as much as 8% in European morning trading Tuesday.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-jump-after-fda-approves-pill-version-of-wegovy-0c759799?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "bf8133a2-d1be-3610-a031-323528bc57c1",
      "content": {
        "id": "bf8133a2-d1be-3610-a031-323528bc57c1",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy",
        "description": "",
        "summary": "Novo Nordisk  shares climbed after U.S. regulators approved a tablet version of Ozempic and Wegovy, paving the way for the Danish drugmaker to start selling the first GLP-1 weight-loss pill.  The Food and Drug Administration’s green light is expected to broaden the use of the class of drugs to which Novo Nordisk’s Ozempic and Wegovy and  Eli Lilly’s  Zepbound and Mounjaro belong, ushering in a new era of the obesity-drug revolution.  Shares in Novo Nordisk rose as much as 8% in European morning trading Tuesday.",
        "pubDate": "2025-12-23T10:05:00Z",
        "displayTime": "2025-12-23T10:05:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/bf8133a2-d1be-3610-a031-323528bc57c1/novo-nordisk-shares-jump.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e0BgLnvPpwyh7Pjsw4EP6Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jTiPV.FuS9unTJ78fAHifQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/e83d2d773541faef04f98d3a409db389.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-jump-after-fda-approves-pill-version-of-wegovy-0c759799?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T09:43:00+00:00",
    "headline": "Pill Version of Wegovy Is Approved for Use in the U.S.",
    "summary": "Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.",
    "url": "https://www.wsj.com/health/pharma/pill-version-of-wegovy-is-approved-for-use-in-the-u-s-6d6a6f2d?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "4c8488a3-403f-3c55-9b54-702e7df9bb01",
      "content": {
        "id": "4c8488a3-403f-3c55-9b54-702e7df9bb01",
        "contentType": "STORY",
        "title": "Pill Version of Wegovy Is Approved for Use in the U.S.",
        "description": "",
        "summary": "Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.",
        "pubDate": "2025-12-23T09:43:00Z",
        "displayTime": "2025-12-23T09:43:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4c8488a3-403f-3c55-9b54-702e7df9bb01/pill-version-of-wegovy-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1SHu8WUYGwFvreI1qVJ2A--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RApsOqmUMyIICUUqEeo1RQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/b7bac580d0e2d6936caa363e49f1ff94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/pill-version-of-wegovy-is-approved-for-use-in-the-u-s-6d6a6f2d?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:37:23+00:00",
    "headline": "Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity",
    "summary": "Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.",
    "url": "https://www.pharmaceutical-technology.com/news/novo-beats-lilly-to-first-fda-approved-glp-1ra-pill-for-obesity/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "53729f95-fb09-30bb-a0ee-966d6dd3414c",
      "content": {
        "id": "53729f95-fb09-30bb-a0ee-966d6dd3414c",
        "contentType": "STORY",
        "title": "Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity",
        "description": "",
        "summary": "Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.",
        "pubDate": "2025-12-23T11:37:23Z",
        "displayTime": "2025-12-23T11:37:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RseODmWOW4IbPIp37PX_zA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UCyGFLu6xa6Cw8DriKhedg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/5d155d94aaf29bc9aa871cd56ba8eeab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/novo-beats-lilly-to-first-fda-approved-glp-1ra-pill-for-obesity/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-beats-lilly-first-fda-113723797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T11:28:23+00:00",
    "headline": "Novo Nordisk Jumps 7% After FDA Approves First Ever GLP-1 Pill",
    "summary": "Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "9ac2e64f-67dc-3b4b-8832-c32f7e734a40",
      "content": {
        "id": "9ac2e64f-67dc-3b4b-8832-c32f7e734a40",
        "contentType": "STORY",
        "title": "Novo Nordisk Jumps 7% After FDA Approves First Ever GLP-1 Pill",
        "description": "",
        "summary": "Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.",
        "pubDate": "2025-12-23T11:28:23Z",
        "displayTime": "2025-12-23T11:28:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-jumps-7-fda-112823474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-23T10:48:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, Zim, and More",
    "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
    "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
      "content": {
        "id": "dcb96691-f52a-395f-be81-e7695e1ffdcb",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Novo Nordisk, Eli Lilly, Huntington Ingalls, Micron, DJT, Zim, and More",
        "description": "",
        "summary": "Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.",
        "pubDate": "2025-12-23T10:48:00Z",
        "displayTime": "2025-12-23T10:48:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dcb96691-f52a-395f-be81-e7695e1ffdcb/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDwEUpGkdEDr789NVbU8CA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tKnpo.hIxRqi7QH6r_KIGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c4586b86e1119b6efab06dbba56da84f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-258b2b54?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HII"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "ZIM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]